Antisense Therapy for Infectious Diseases
暂无分享,去创建一个
[1] Yeonjoon Kim. Drug Discovery Perspectives of Antisense Oligonucleotides , 2023, Biomolecules & therapeutics.
[2] A. Chinnaiyan,et al. Antisense oligonucleotides to therapeutically target SARS-CoV-2 infection , 2023, PloS one.
[3] M. Imamura,et al. Phase IIa, randomised, double-blind study of GSK3389404 in patients with chronic hepatitis B on stable nucleos(t)ide therapy. , 2022, Journal of hepatology.
[4] W. Tarn,et al. Antisense Oligonucleotide-Based Therapy of Viral Infections , 2021, Pharmaceutics.
[5] E. Mercuri,et al. Long-Term Safety and Efficacy Data of Golodirsen in Ambulatory Patients with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A First-in-human, Multicenter, Two-Part, Open-Label, Phase 1/2 Trial , 2021, Nucleic acid therapeutics.
[6] S. P. Parihar,et al. Targeting Molecular Inflammatory Pathways in Granuloma as Host-Directed Therapies for Tuberculosis , 2021, Frontiers in Immunology.
[7] P. Shieh,et al. Safety, tolerability, and pharmacokinetics of casimersen in patients with Duchenne muscular dystrophy amenable to exon 45 skipping: A randomized, double‐blind, placebo‐controlled, dose‐titration trial , 2021, Muscle & nerve.
[8] J. Mendell,et al. Open-Label Evaluation of Eteplirsen in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping: PROMOVI Trial , 2021, Journal of neuromuscular diseases.
[9] Annemieke Aartsma-Rus,et al. Delivery of oligonucleotide‐based therapeutics: challenges and opportunities , 2021, EMBO molecular medicine.
[10] M. Gagliardi,et al. The Challenges and Strategies of Antisense Oligonucleotide Drug Delivery , 2021, Biomedicines.
[11] S. Crooke,et al. Antisense technology: an overview and prospectus , 2021, Nature Reviews Drug Discovery.
[12] R. Pettigrew,et al. The Limitless Future of RNA Therapeutics , 2021, Frontiers in Bioengineering and Biotechnology.
[13] Laura Michelle Streicher. Exploring the future of infectious disease treatment in a post-antibiotic era: A comparative review of alternative therapeutics. , 2021, Journal of global antimicrobial resistance.
[14] K. Jamialahmadi,et al. Antisense Oligonucleotide (AS‐ODN) Technology: Principle, Mechanism and Challenges , 2020, Biotechnology and applied biochemistry.
[15] R. Langer,et al. Advances in oligonucleotide drug delivery , 2020, Nature Reviews Drug Discovery.
[16] Shuaijian Ni,et al. Recent Progress in Aptamer Discoveries and Modifications for Therapeutic Applications. , 2020, ACS applied materials & interfaces.
[17] Harukazu Suzuki,et al. Host-directed targeting of lincRNA-MIR99AHG suppresses intracellular growth of Mycobacterium tuberculosis , 2020, Nucleic acid therapeutics.
[18] A. Vikram,et al. Antisense Oligonucleotides: An Emerging Area in Drug Discovery and Development , 2020, Journal of clinical medicine.
[19] Robert J. Lee,et al. Cell-Penetrating Peptides in Diagnosis and Treatment of Human Diseases: From Preclinical Research to Clinical Application , 2020, Frontiers in Pharmacology.
[20] S. Crooke,et al. Phosphorothioate modified oligonucleotide–protein interactions , 2020, Nucleic acids research.
[21] K. Shi,et al. Structural basis of receptor recognition by SARS-CoV-2 , 2020, Nature.
[22] C. Foged,et al. Opportunities and Challenges in the Delivery of mRNA-Based Vaccines , 2020, Pharmaceutics.
[23] P. Barthélémy,et al. Lipid oligonucleotides as a new strategy for tackling the antibiotic resistance , 2020, Scientific Reports.
[24] Li-Min Huang,et al. The Host Heat Shock Protein MRJ/DNAJB6 Modulates Virus Infection , 2019, Front. Microbiol..
[25] J. Kawai,et al. Evaluation of off‐target effects of gapmer antisense oligonucleotides using human cells , 2019, Genes to cells : devoted to molecular & cellular mechanisms.
[26] Jinkuk Kim,et al. Patient-Customized Oligonucleotide Therapy for a Rare Genetic Disease. , 2019, The New England journal of medicine.
[27] D. Stetsenko,et al. A New Antisense Phosphoryl Guanidine Oligo-2′-O-Methylribonucleotide Penetrates Into Intracellular Mycobacteria and Suppresses Target Gene Expression , 2019, Front. Pharmacol..
[28] J. Rossi,et al. Dual Mechanisms of Action of Self-Delivering, Anti-HIV-1 FANA Oligonucleotides as a Potential New Approach to HIV Therapy , 2019, Molecular therapy. Nucleic acids.
[29] Christopher E. Hart,et al. Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index , 2019, Nature Biotechnology.
[30] Christopher E. Hart,et al. Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index , 2019, Nature Biotechnology.
[31] S. Pulst,et al. Antisense oligonucleotides , 2019, Neurology: Genetics.
[32] P. Yenchitsomanus,et al. Inhibition of dengue virus replication in monocyte-derived dendritic cells by vivo-morpholino oligomers. , 2019, Virus research.
[33] S. Altman,et al. Mesyl phosphoramidate antisense oligonucleotides as an alternative to phosphorothioates with improved biochemical and biological properties , 2019, Proceedings of the National Academy of Sciences.
[34] Luan-Yin Chang,et al. Interference of DNAJB6/MRJ Isoform Switch by Morpholino Inhibits Replication of HIV-1 and RSV , 2018, Molecular therapy. Nucleic acids.
[35] S. Kauppinen,et al. Development of Locked Nucleic Acid Antisense Oligonucleotides Targeting Ebola Viral Proteins and Host Factor Niemann-Pick C1. , 2018, Nucleic acid therapeutics.
[36] A. Goyenvalle,et al. Exon-skipping advances for Duchenne muscular dystrophy. , 2018, Human molecular genetics.
[37] S. Dowdy,et al. GalNAc-siRNA Conjugates: Leading the Way for Delivery of RNAi Therapeutics. , 2018, Nucleic acid therapeutics.
[38] Yanjin Zhang,et al. Antisense Phosphorodiamidate Morpholino Oligomers as Novel Antiviral Compounds , 2018, Front. Microbiol..
[39] J. Young,et al. Liver-Targeted Anti-HBV Single-Stranded Oligonucleotides with Locked Nucleic Acid Potently Reduce HBV Gene Expression In Vivo , 2018, Molecular therapy. Nucleic acids.
[40] J. Hegarty,et al. Advances in therapeutic bacterial antisense biotechnology , 2017, Applied Microbiology and Biotechnology.
[41] T. Tagami,et al. Recent Trends in Clinical Trials Related to Carrier-Based Drugs. , 2017, Journal of pharmaceutical sciences.
[42] H. Bui,et al. Antisense oligonucleotides targeting translation inhibitory elements in 5′ UTRs can selectively increase protein levels , 2017, Nucleic acids research.
[43] S. Dowdy. Overcoming cellular barriers for RNA therapeutics , 2017, Nature Biotechnology.
[44] J. Goldberg,et al. Inhibition of Pseudomonas aeruginosa by Peptide-Conjugated Phosphorodiamidate Morpholino Oligomers , 2017, Antimicrobial Agents and Chemotherapy.
[45] B. Baker,et al. Pharmacology of Antisense Drugs. , 2017, Annual review of pharmacology and toxicology.
[46] Jessica Chery. RNA therapeutics: RNAi and antisense mechanisms and clinical applications. , 2016, Postdoc journal : a journal of postdoctoral research and postdoctoral affairs.
[47] E. McNally,et al. Welcome to the splice age: antisense oligonucleotide-mediated exon skipping gains wider applicability. , 2016, The Journal of clinical investigation.
[48] Abolfazl Akbarzadeh,et al. Application of liposomes in medicine and drug delivery , 2016, Artificial cells, nanomedicine, and biotechnology.
[49] L. Good,et al. Oxacillin sensitization of methicillin-resistant Staphylococcus aureus and methicillin-resistant Staphylococcus pseudintermedius by antisense peptide nucleic acids in vitro , 2015, BMC Microbiology.
[50] S. Crooke,et al. The rates of the major steps in the molecular mechanism of RNase H1-dependent antisense oligonucleotide induced degradation of RNA , 2015, Nucleic acids research.
[51] Reto Guler,et al. Host-directed drug therapy for tuberculosis. , 2015, Nature chemical biology.
[52] M. Wood,et al. An overview of the clinical application of antisense oligonucleotides for RNA-targeting therapies. , 2015, Current opinion in pharmacology.
[53] Choukri Ben Mamoun,et al. Targeting protein translation, RNA splicing, and degradation by morpholino-based conjugates in Plasmodium falciparum , 2015, Proceedings of the National Academy of Sciences.
[54] K. Kataoka,et al. DNA/RNA heteroduplex oligonucleotide for highly efficient gene silencing , 2015, Nature Communications.
[55] Fritz Eckstein,et al. Phosphorothioates, essential components of therapeutic oligonucleotides. , 2014, Nucleic acid therapeutics.
[56] X. Xue,et al. Antisense Growth Inhibition of Methicillin-Resistant Staphylococcus aureus by Locked Nucleic Acid Conjugated with Cell-Penetrating Peptide as a Novel FtsZ Inhibitor , 2014, Antimicrobial Agents and Chemotherapy.
[57] L. van Doorn,et al. In Vitro Antiviral Activity and Preclinical and Clinical Resistance Profile of Miravirsen, a Novel Anti-Hepatitis C Virus Therapeutic Targeting the Human Factor miR-122 , 2014, Antimicrobial Agents and Chemotherapy.
[58] S. Crooke,et al. Antisense Oligonucleotides Capable of Promoting Specific Target mRNA Reduction via Competing RNase H1-Dependent and Independent Mechanisms , 2014, PloS one.
[59] W. Witola,et al. Silencing of GRA10 protein expression inhibits Toxoplasma gondii intracellular growth and development. , 2014, Parasitology international.
[60] Shuling Guo,et al. Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice , 2014, Nucleic acids research.
[61] K. Mikoshiba,et al. Antisense Oligonucleotides Targeting Parasite Inositol 1,4,5-Trisphosphate Receptor Inhibits Mammalian Host Cell Invasion by Trypanosoma cruzi , 2014, Scientific Reports.
[62] Ü. Langel,et al. Cell-penetrating peptides: design, synthesis, and applications. , 2014, ACS nano.
[63] Jing Yang,et al. Pretreatment of Mice with Oligonucleotide prop5 Protects Them from Influenza Virus Infections , 2014, Viruses.
[64] David E Greenberg,et al. Gene-silencing antisense oligomers inhibit acinetobacter growth in vitro and in vivo. , 2013, The Journal of infectious diseases.
[65] Sidney Altman,et al. A peptide-morpholino oligomer conjugate targeting Staphylococcus aureus gyrA mRNA improves healing in an infected mouse cutaneous wound model. , 2013, International journal of pharmaceutics.
[66] M. Seleem,et al. Targeting listeria monocytogenes rpoA and rpoD genes using peptide nucleic acids. , 2013, Nucleic acid therapeutics.
[67] T. Gilberger,et al. PfSec13 is an unusual chromatin-associated nucleoporin of Plasmodium falciparum that is essential for parasite proliferation in human erythrocytes , 2013, Journal of Cell Science.
[68] J. Setubal,et al. Peptide nucleic acids inhibit growth of Brucella suis in pure culture and in infected murine macrophages. , 2013, International journal of antimicrobial agents.
[69] D. Corey,et al. Silencing disease genes in the laboratory and the clinic , 2012, The Journal of pathology.
[70] G. Pauli,et al. Human Cytomegalovirus (HCMV) – Revised , 2010, Transfusion Medicine and Hemotherapy.
[71] S. Oh,et al. A highly effective and long-lasting inhibition of miRNAs with PNA-based antisense oligonucleotides , 2009, Molecules and cells.
[72] R. Crouch,et al. Ribonuclease H: the enzymes in eukaryotes , 2009, The FEBS journal.
[73] H. Feldmann,et al. The Ebola virus ribonucleoprotein complex: a novel VP30-L interaction identified. , 2009, Virus research.
[74] G. Ruthel,et al. Chemical Modifications of Antisense Morpholino Oligomers Enhance Their Efficacy against Ebola Virus Infection , 2009, Antimicrobial Agents and Chemotherapy.
[75] S. P. Walton,et al. Impact of target mRNA structure on siRNA silencing efficiency: A large‐scale study , 2008, Biotechnology and bioengineering.
[76] D. A. Stein,et al. Inhibition of respiratory syncytial virus infections with morpholino oligomers in cell cultures and in mice. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.
[77] A. Judge,et al. Overcoming the innate immune response to small interfering RNA. , 2008, Human gene therapy.
[78] K. Spurgers,et al. Oligonucleotide antiviral therapeutics: Antisense and RNA interference for highly pathogenic RNA viruses , 2008, Antiviral Research.
[79] M. Gait,et al. miR-122 targeting with LNA/2'-O-methyl oligonucleotide mixmers, peptide nucleic acids (PNA), and PNA-peptide conjugates. , 2007, RNA.
[80] Brenda F Baker,et al. Enhancement of SMN2 Exon 7 Inclusion by Antisense Oligonucleotides Targeting the Exon , 2007, PLoS biology.
[81] Shunqing Xu,et al. Inositol-1-phosphate synthetase mRNA as a new target for antisense inhibition of Mycobacterium tuberculosis. , 2007, Journal of biotechnology.
[82] D. A. Stein,et al. Inhibition of Multiple Subtypes of Influenza A Virus in Cell Cultures with Morpholino Oligomers , 2006, Antimicrobial Agents and Chemotherapy.
[83] Shuhui Lim,et al. ANTISENSE OLIGONUCLEOTIDES: FROM DESIGN TO THERAPEUTIC APPLICATION , 2006, Clinical and experimental pharmacology & physiology.
[84] X. Bo,et al. Antisense oligonucleotides targeted against asialoglycoprotein receptor 1 block human hepatitis B virus replication , 2006, Journal of viral hepatitis.
[85] D. A. Stein,et al. Inhibition of dengue virus translation and RNA synthesis by a morpholino oligomer targeted to the top of the terminal 3' stem-loop structure. , 2006, Virology.
[86] Yin Chen,et al. Peptide Nucleic Acid Antisense Oligomer as a Therapeutic Strategy against Bacterial Infection: Proof of Principle Using Mouse Intraperitoneal Infection , 2005, Antimicrobial Agents and Chemotherapy.
[87] E. Harris,et al. Enhancement of dengue virus translation: role of the 3' untranslated region and the terminal 3' stem-loop domain. , 2004, Virology.
[88] S. Crooke,et al. Determination of the Role of the Human RNase H1 in the Pharmacology of DNA-like Antisense Drugs* , 2004, Journal of Biological Chemistry.
[89] L. Hubbard,et al. A randomized controlled clinical trial of intravitreous fomivirsen for treatment of newly diagnosed peripheral cytomegalovirus retinitis in patients with AIDS , 2002 .
[90] G J van den Horn,et al. Fomivirsen: a phosphorothioate oligunucleotide for the treatment of CMV retinitis , 1999 .
[91] R. Padmanabhan,et al. A Novel in Vitro Replication System for Dengue Virus , 1999, The Journal of Biological Chemistry.
[92] S. Mande,et al. Identification of the INO1 gene of Mycobacterium tuberculosis H37Rv reveals a novel class of inositol-1-phosphate synthase enzyme. , 1999, Journal of molecular biology.
[93] B. Roehr. Fomivirsen approved for CMV retinitis. , 1998, Journal of the International Association of Physicians in AIDS Care.
[94] S. Agrawal,et al. Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: in vitro and in vivo studies. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[95] Z. Dominski,et al. RNase H cleavage of RNA hybridized to oligonucleotides containing methylphosphonate, phosphorothioate and phosphodiester bonds , 1989 .
[96] A. Lamond,et al. Highly efficient chemical synthesis of 2'-O-methyloligoribonucleotides and tetrabiotinylated derivatives; novel probes that are resistant to degradation by RNA or DNA specific nucleases. , 1989, Nucleic acids research.
[97] K. Jayaraman,et al. Selective inhibition of Escherichia coli protein synthesis and growth by nonionic oligonucleotides complementary to the 3' end of 16S rRNA. , 1981, Proceedings of the National Academy of Sciences of the United States of America.
[98] R. New,et al. Antileishmanial activity of antimonials entrapped in liposomes , 1978, Nature.
[99] V. Arechavala-Gomeza,et al. Antisense RNA Therapeutics: A Brief Overview. , 2022, Methods in molecular biology.
[100] D. Klinman,et al. CpG Oligonucleotides as Vaccine Adjuvants. , 2021, Methods in molecular biology.
[101] T. Yokota,et al. DNA-RNA Heteroduplex Oligonucleotide for Highly Efficient Gene Silencing. , 2020, Methods in molecular biology.
[102] K. E. Lundin,et al. Chemical Development of Therapeutic Oligonucleotides. , 2019, Methods in molecular biology.
[103] Diou Luo,et al. Pre-mRNA Splicing Modulation by Antisense Oligonucleotides. , 2018, Methods in molecular biology.
[104] R. Persson,et al. Locked nucleic acid: modality, diversity, and drug discovery. , 2018, Drug discovery today.
[105] Y. Kong,et al. Antimicrobial activity of antisense peptide–peptide nucleic acid conjugates against non-typeable Haemophilus influenzae in planktonic and biofilm forms , 2017, The Journal of antimicrobial chemotherapy.
[106] Shumei Liang,et al. Inhibiting the growth of methicillin-resistant Staphylococcus aureus in vitro with antisense peptide nucleic acid conjugates targeting the ftsZ gene. , 2015, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.
[107] Y. Hua,et al. Antisense-mediated exon inclusion. , 2012, Methods in molecular biology.
[108] Richard S Geary,et al. Fomivirsen: clinical pharmacology and potential drug interactions. , 2002, Clinical pharmacokinetics.
[109] M. Cornish,et al. A randomized controlled clinical trial of intravitreous fomivirsen for treatment of newly diagnosed peripheral cytomegalovirus retinitis in patients with AIDS. , 2002, American journal of ophthalmology.
[110] M. Stephenson,et al. Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. , 1978, Proceedings of the National Academy of Sciences of the United States of America.